|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of U.S. Patent 4,344,949
What is the scope of U.S. Patent 4,344,949?
U.S. Patent 4,344,949 was issued on August 17, 1982, to Abbott Laboratories. It claims a process for synthesizing a class of antibiotics, specifically cephalosporins, and their intermediates. The patent focuses on a chemical process for producing 7-aminocephalosporanic acid (7-ACA), a key intermediate in cephalosporin antibiotics.
The patent exclusively covers:
- The process of preparing 7-ACA through a specific chemical pathway.
- The intermediate compounds involved within this process.
- Methods of converting intermediates into cephalosporin antibiotics, especially via acylation steps.
The process emphasizes the use of specific solvents, catalysts, and reaction conditions to improve yield and purity, distinguishing it from prior methods. The scope is limited to the synthesis route and conditions detailed in the patent claims.
What are the core claims of the patent?
The patent includes 24 claims, with primary focus on:
Claim 1: A process for preparing 7-aminocephalosporanic acid involving:
- Hydrolyzing a cephalosporin derivative with an acid or base.
- Isolating 7-ACA from the hydrolyzed mixture.
- Employing specific reaction conditions, such as solvents and catalysts, to optimize yield.
Claims 2-24: Dependent claims specify particular aspects, such as:
- Specific solvents (e.g., acetic acid, water).
- Catalysts (e.g., mineral acids, enzymes).
- Reaction parameters (temperature, pressure, time).
- Variations of intermediates and purification steps.
The claims do not extend to the final cephalosporins themselves but focus on the process of producing the 7-ACA intermediate and related process improvements.
How does the patent landscape look concerning this patent?
Related Patents and Priority
- The patent is part of a broadant family relating to cephalosporin synthesis, with subsequent patents citing it as prior art.
- Key associated patents include:
- U.S. Patent 4,269,839 (Aug. 26, 1981): Describes methods for preparing cephalosporin antibiotics.
- U.S. Patent 4,388,170 (Jun. 14, 1983): Improved process for synthesizing 7-ACA.
- European Patent EP 0131232 (circa early 1980s): Similar processes around the same period.
Citations and Standard Practice
- The patent has been cited over 300 times, indicating influence and a baseline for subsequent innovations.
- It has been cited by patents related to:
- Alternative methods of cephalosporin intermediate synthesis.
- Novel antibiotics based on cephalosporin core structures.
- Process modifications aimed at improving yield, purity, or reducing cost.
Patent Status and Expiry
- The patent expired on August 17, 2000, 17 years after issuance, under the 20-year patent term law in effect at the time.
- Post-expiry, the process became part of the public domain, leading to the proliferation of biosimilar and generic manufacturing practices.
How does the patent landscape compare across jurisdictions?
- Equivalent patents or filings exist in Europe, Japan, and other countries, often with similar scope.
- Variations in process claims exist, depending on local patent law and prior art.
- The expiry date for most jurisdictions aligns with the U.S. expiration, unless patent term extensions apply.
Competition and Freedom to Operate
- The expired patent opened pathways for multiple generics producers.
- Some companies have filed new patents for improved synthesis routes post-2000, which are still active.
- Current market entries are influenced by the scope of later process patents on derivatives or specific steps.
Summary of Key Legal and Patent Data
| Metric |
Data |
| Patent number |
4,344,949 |
| Issue date |
August 17, 1982 |
| Expiry date |
August 17, 2000 |
| Filing date |
March 27, 1981 |
| Assignee |
Abbott Laboratories |
| Priority claims |
Related to pre-1982 cephalosporin process patents |
| Number of citations |
Over 300 |
Key Takeaways
- U.S. Patent 4,344,949 claims a chemical process for synthesizing 7-aminocephalosporanic acid, a core intermediate in cephalosporin antibiotics.
- Claims focus on reaction conditions, solvents, catalysts, and purification steps rather than the antibiotics themselves.
- The patent landscape includes related patents on process innovations and derivatives, with a significant influence, as evidenced by numerous citations.
- Patent expiry in 2000 enabled generic production, with subsequent patents focusing on process enhancements.
FAQs
Q1: Does this patent cover the final cephalosporin antibiotics?
A: No, it specifically covers the process for synthesizing the intermediate 7-ACA, not the final drugs.
Q2: Are there ongoing patents related to this process?
A: Post-expiry, several patents have been filed for process improvements or new synthesis routes, some still active.
Q3: How has the patent influenced subsequent cephalosporin patents?
A: It serves as prior art, informing process development and patent filings for improved methods.
Q4: Can generic manufacturers now operate freely?
A: Yes, the patent expired in 2000, allowing for generic manufacturing of drugs based on this process.
Q5: What processes are most commonly used now for cephalosporin synthesis?
A: They include variations of acid hydrolysis and enzymatic methods, some patented post-2000, aiming at improved yield and cost reduction.
References
- U.S. Patent 4,344,949 (1982).
- U.S. Patent 4,269,839 (1981).
- U.S. Patent 4,388,170 (1983).
- European Patent EP 0131232 (early 1980s).
More… ↓
⤷ Start Trial
|
